Humane Genomics logo

Humane Genomics

Emerging

Synthetic oncolytic virus biotech engineering programmable cancer-killing RNA viruses; $8.12M raised with Union Square Ventures leading 2025 round competing in cancer immunotherapy.

30
AI Score
Grade D↑ Trending
AI Visibility Score (Beta)
HealthcareWebsiteUpdated March 2026

Company Overview

About Humane Genomics

Humane Genomics is a synthetic virology biotech company engineering oncolytic viruses — synthetic RNA viruses designed to selectively infect and destroy cancer cells while leaving healthy cells unharmed — using a proprietary platform that programs viral behavior at the genomic level to create next-generation cancer therapies. The company raised $8.12 million in total funding including a February 2025 round led by Union Square Ventures with 14 investor participants, developing RNA-based viral cancer therapies for systemic delivery designed for extended therapeutic activity.

Business Model & Competitive Advantage

Humane Genomics' synthetic virology platform enables precise engineering of viral genomes to control which cell types the virus infects (cancer cell selectivity through tumor-specific entry mechanisms and replication-dependent killing), how long the virus remains active, and what payloads the virus carries (immune-stimulating transgenes that activate anti-tumor immune responses alongside direct viral killing). The synthetic approach, building viruses from scratch rather than modifying natural viruses, enables more precise control over safety and efficacy characteristics than naturally derived oncolytic virus platforms.

Competitive Landscape 2025–2026

In 2025, Humane Genomics competes in the oncolytic virus and cancer immunotherapy market with Genelux (GL-ONC1), Imvax, Replimune (REPL), and the broader cancer immunotherapy pipeline including checkpoint inhibitors and CAR-T for solid tumor oncology. Oncolytic virotherapy has seen renewed interest as the cancer immunotherapy field looks beyond checkpoint inhibitors (PD-1/PD-L1) for approaches that work in immunologically "cold" tumors that don't respond to immune checkpoint blockade. Union Square Ventures' lead investment reflects the growing biotech-focused investment activity at traditionally software-focused growth funds. The 2025 strategy focuses on preclinical validation of the synthetic virology platform, advancing lead programs toward IND-enabling studies, and building the manufacturing process for synthetic RNA virus production at clinical scale.

Curated content • Fact-checked and verified

Recent Activity

View all →

Key Differentiators

Emerging Innovator

Humane Genomics is an emerging player bringing innovative solutions to the Healthcare market.

Frequently Asked Questions

Estimated Visibility Trend (Beta)

Simulated 8-week rolling score

30
↑ Trending

Based on estimated brand signals. Historical tracking coming soon.

Similar Brands

Browser Use logo

Browser Use

Developer Tools
B2bDeveloper ToolsPlatformSaasStartup

Browser Use is an open-source project that provides a Python library allowing AI agents and large language models to control web browsers as a tool. The library sits between LLM APIs and browser autom

athenahealth logo

athenahealth

Healthcare
B2bCloud NativeEnterpriseErpHealthtechNorth AmericaSaas

athenahealth is a cloud-based electronic health records (EHR), medical billing, and practice management company founded in 1997 and headquartered in Watertown, Massachusetts. The company was built on

Veeva Systems logo

Veeva Systems

Healthcare Tech
B2bHealthtechSaasPublic

Veeva Systems Inc. is the leading cloud software provider for the global life sciences industry, headquartered in Pleasanton, California. Founded in 2007 by Peter Gassner (a former Salesforce executiv

Oracle Health logo

Oracle Health

Healthcare
HealthtechNorth AmericaB2b

Oracle Health is the healthcare technology business unit of Oracle Corporation (NYSE: ORCL) — providing electronic health records (EHR), clinical workflow management, health information exchange, reve

Idexx Laboratories logo

Idexx Laboratories

Healthcare Tech
B2bHealthtechManufacturingSaasPublic

IDEXX Laboratories is the global leader in veterinary diagnostics and information technology for companion animal healthcare, founded in 1983 by David Shaw in Westbrook, Maine, where it remains headqu

Revvity logo

Revvity

Healthcare Tech
B2bHealthtechManufacturingSaasPublic

Revvity, Inc. (formerly PerkinElmer) is a global life science tools and diagnostics company, rebranded in 2023 to signal its transformation from a diversified instruments company into a focused provid

For Humane Genomics

Claim This Profile

Are you from Humane Genomics? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.

Claim Humane Genomics Profile →
For competitors & analysts

Track AI Visibility in Real Time

Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Humane Genomics vs competitors. Get alerts when AI recommendations shift.

Start Free Tracking →